11 Best Australian Stocks to Buy According to Analysts

Page 3 of 10

8. Mesoblast Limited (NASDAQ:MESO)

Number of Hedge Fund Holders: 2

Analyst Upside Potential: 101.51%

Mesoblast Limited (NASDAQ:MESO) is another Australian biotechnology company that develops and commercializes allogeneic cellular medicines. These medicines are designed to treat severe inflammatory and immune-mediated conditions. The company uses its proprietary mesenchymal lineage cell therapy technology platform to develop a broad portfolio of late-stage product candidates.

On May 1, Bell Potter analyst John Hester maintained a Buy rating on the stock with a price target of A$3.40. The company recently underwent significant strategic and financial developments. The company got its key product, Ryoncil, approved by the FDA. The product has become the first mesenchymal stromal cell therapy approved by the US FDA to treat steroid-refractory acute graft versus host disease in children. Mesoblast Limited (NASDAQ:MESO) is leveraging its strong cash position to expand Ryoncil indications to other serious pediatric inflammatory conditions. Management noted that Ryoncil will be available for use in steroid-refractory acute GVHD in the United States this quarter, and studies will be initiated for pediatric and adult label extension indications. Mesoblast Limited (NASDAQ:MESO) is one of the best Australian stocks to buy according to analysts.

Page 3 of 10